Home » Newsletters » BioWorld Science

BioWorld Science

June 16, 2020

View Archived Issues

Identification of oral hydroxpyridinone iron chelator for the treatment of iron overload

"Gastruloids" enable study of embryonic development

ApoE4's role in Alzheimer's blood vessels

Neurocrine Biosciences reports positive results with crinecerfont in congenital adrenal hyperplasia

SARS-CoV-2 neutralizing MAb identified from memory B cells of an individual infected with SARS-CoV

RemeGen studies RC-88 in phase I for advanced malignant solid tumors

MT-7117 enters phase III for erythropoietic protoporphyria and X-linked protoporphyria

[18F]EKZ-001 PET radioligand targeting brain HDAC6: cGMP production and target occupancy in NHPs

Antisense PNAs targeting lpxB gene inhibit A. baumannii growth and synergize with colistin

Bayer initiates phase III FINEARTS-HF study of finerenone in heart failure

First patient dosed in phase II study of ATYR-1923 in COVID-19 with severe respiratory complications

PDS Biotech and NCI initiate phase II study of PDS-0101

Pivotal trial of darinaparsin in peripheral T-cell lymphoma meets primary endpoint

Cue Biopharma advances phase I study of CUE-101 in head and neck cancer

RICTOR as a new therapeutic target for lung cancer brain metastases

Phase II data presented from ORIENT-2 study of sintilimab advanced refractory ESCC

New SHP-2 inhibitors identified at Tuojie Biotech

Shanghai Pharmaceuticals Holding patents MAPK11 and 14 inhibitors

New Mnk1 and Mnk2 inhibitors discovered at Shanghai De Novo Pharmatech

New dual CDK-HDAC inhibitors synthesized at Hangzhou Innogate Pharma

Janssen discovers compounds active against respiratory syncytial virus

The Treg-selective long-acting IL-2 variant CUG-252 reduces inflammation in vitro and in vivo

Favorable safety, pharmacodynamic activity seen with FT-4202 in phase I study

FDA grants accelerated approval to Zepzelca for metastatic SCLC

Janssen plans phase II development of JNJ-40411813 for epilepsy

Phase IIb study of lanifibranor in NASH meets primary and key secondary endpoints

FDA approves Lyumjev for type 1 and type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...